Skip to main content
. 2014 Jan 16;5(5):1265–1278. doi: 10.18632/oncotarget.1711

Figure 4. Antitumor effects in combination with EGFR endocytosis inhibitor and gefitinib in a xenograft mouse model.

Figure 4

(A) Gefitinib-insensitive SNU-1327 cells were inoculated subcutaneously and the mice were treated with DMSO, dynasore (30 mg/kg, 2 days/week), gefitinib (5 mg/kg, 4 days/week), dynasore (30 mg/kg) plus gefitinib (5 mg/kg) intraperitoneally for 3 weeks, and mean tumor volume with standard error were plotted. * p < 0.05. (B) Hematoxylin and eosin (H&E), Ki67, and TUNEL staining of representative tissue sections from tumors in each mouse group. Yellow scale bar is 100 μm.